Cipher Pharmaceuticals Inc. (TSX: CPH)
Health Care · Pharmaceuticals · CA
CA$14.10
0.00% today · -6.6% 1Y
Cipher Pharmaceuticals Inc. (TSX: CPH) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $260.26M and employs 5 people.
Over the last twelve months the share price has lost 6.6%, trading between 12.48 and 20.56.
Tweenvest scores Cipher Pharmaceuticals Inc. across four factors: quality 77/100, value 48/100, growth 80/100. Its strongest factor is growth.
CPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $260.26M
- Revenue (TTM)
- $49.62M
- P/E
- 8.84
- EPS
- 1.12
- Dividend yield
- —
- Beta (5Y)
- 0.46
- 52-week high
- CA$20.56
- 52-week low
- CA$12.48
- Avg volume (3M)
- —
- Shares outstanding
- 25.42M
- Employees
- 5
- Next earnings
- —
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
- ISIN
- CA17253X1050
- Founded
- 2000
- Listed since
- May 7, 2004
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.